Karyotype and ASXL1 mutation in patients with OM
| CG characteristics . | N . | OM type (N)* . | ||||
|---|---|---|---|---|---|---|
| Patients . | SX/OBS . | XRT . | CHT . | CMT . | ||
| Diploid | 82 | 54 | 7 | 8 | 6 | Melanoma (20), prostate (30), CRC (12), breast (8), RCC (3), bladder (6), HEM. (7), GEN (10), others† (12) |
| Clonal abnormality | 39 | 20 | 8 | 8 | 3 | — |
| Del 20q | 8 | 6 | 1 | 1 | Melanoma (4), CRC (1), prostate (4), CLL (1), RCC (2) | |
| Del 13q | 7 | 2 | 2 | 2 | 1 | CRC (2), RCC (1), melanoma (1), prostate (3), B-NHL (1) |
| Del 5/5q | 3 | 2 | 1 | CLL (1), breast (2), B-NHL (1) | ||
| Del 7/7q | 2 | 2 | Prostate (2) | |||
| Del 11q23 | 1 | 1 | B-NHL(1), breast (1) | |||
| Trisomy 8 | 3 | 1 | 1 | 1 | Thyroid (2), B-NHL (1) | |
| Complex | 2 | 1 | 1 | Prostate (1), cervix (1) | ||
| Other clonal abnormalities‡ | 13 | 10 | 1 | 2 | Bladder (1), prostate (5), CRC (1), RCC (2), sar. SCC (1), melanoma (1), CLL (2), breast (1), thyroid (1) | |
| ASXL1 mutation§ | ||||||
| ASXL1 (+) | 3 | 3 | Breast (1), vulva (1), B-NHL (1) | |||
| ASXL1 (+) | 6 | 6 | CRC (2), ovary (1), B-NHL (1), CLL (1), breast (1) | |||
| ASXL1 (+) | 5 | 5 | Prostate (3), thyroid (1), uterus (1) | |||
| ASXL1 (−) | 2 | 2 | H&N (1), prostate (1) | |||
| ASXL1 (−) | 9 | 9 | CRC (1), pancreas (1), ovary (1), breast (2), CLL (2), multiple myeloma (1), B-NHL (1) | |||
| ASXL1 (−) | 8 | 8 | Prostate (5), thyroid (1), breast (1), melanoma (1) | |||
| CG characteristics . | N . | OM type (N)* . | ||||
|---|---|---|---|---|---|---|
| Patients . | SX/OBS . | XRT . | CHT . | CMT . | ||
| Diploid | 82 | 54 | 7 | 8 | 6 | Melanoma (20), prostate (30), CRC (12), breast (8), RCC (3), bladder (6), HEM. (7), GEN (10), others† (12) |
| Clonal abnormality | 39 | 20 | 8 | 8 | 3 | — |
| Del 20q | 8 | 6 | 1 | 1 | Melanoma (4), CRC (1), prostate (4), CLL (1), RCC (2) | |
| Del 13q | 7 | 2 | 2 | 2 | 1 | CRC (2), RCC (1), melanoma (1), prostate (3), B-NHL (1) |
| Del 5/5q | 3 | 2 | 1 | CLL (1), breast (2), B-NHL (1) | ||
| Del 7/7q | 2 | 2 | Prostate (2) | |||
| Del 11q23 | 1 | 1 | B-NHL(1), breast (1) | |||
| Trisomy 8 | 3 | 1 | 1 | 1 | Thyroid (2), B-NHL (1) | |
| Complex | 2 | 1 | 1 | Prostate (1), cervix (1) | ||
| Other clonal abnormalities‡ | 13 | 10 | 1 | 2 | Bladder (1), prostate (5), CRC (1), RCC (2), sar. SCC (1), melanoma (1), CLL (2), breast (1), thyroid (1) | |
| ASXL1 mutation§ | ||||||
| ASXL1 (+) | 3 | 3 | Breast (1), vulva (1), B-NHL (1) | |||
| ASXL1 (+) | 6 | 6 | CRC (2), ovary (1), B-NHL (1), CLL (1), breast (1) | |||
| ASXL1 (+) | 5 | 5 | Prostate (3), thyroid (1), uterus (1) | |||
| ASXL1 (−) | 2 | 2 | H&N (1), prostate (1) | |||
| ASXL1 (−) | 9 | 9 | CRC (1), pancreas (1), ovary (1), breast (2), CLL (2), multiple myeloma (1), B-NHL (1) | |||
| ASXL1 (−) | 8 | 8 | Prostate (5), thyroid (1), breast (1), melanoma (1) | |||
B-NHL, B-cell non-Hodgkin lymphoma; CLL, chronic lymphoid leukemia; CRC, colorectal carcinoma; Del, deletion; GEN, genital tract (uterus, cervix, vulva, testes, ovary); H&N, head and neck; HEM, hematologic malignancies (leukemia, lymphoma, myeloma); RCC, renal cell carcinoma; sar. SCC, sarcomatoid squamous cell carcinoma. Other abbreviations are explained in Table 1.
Number of OM with typical characteristics (each OM is calculated separately including patients with >1 OM).
Others indicates sarcoma, CNS, sar. SCC, carcinoma of thyroid, pancreas, and lung.
Structural translocations t(12,18), t(12,21), t(3,12), t(2;11), t(3;15); del 11q13; add 18; or abnormalities of chromosomes 1 and 9 (inversion, balanced translocations, deletions of long arm).
Only patients previously exposed to CHT or radiation therapy.